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Objective: Urinary tract infections (UTIs) are common in the female population and, over a lifetime, about
half of women have at least one episode of UTI requiring antibiotic therapy. The aim of the current study
was to compare two different strategies for preventing recurrent bacterial cystitis: intravesical instilla-
tion of hyaluronic acid (HA) plus chondroitin sulfate (CS), and antibiotic prophylaxis with sulfameth-
oxazole plus trimethoprim.
Materials and methods: This was a retrospective review of two different cohorts of women affected by
recurrent bacterial cystitis. Cases (experimental group) were women who received intravesical in-
stillations of a sterile solution of high concentration of HA þ CS in 50 mL water with calcium chloride
every week during the 1st month and then once monthly for 4 months. The control group included
womenwho received traditional therapy for recurrent cystitis based on daily antibiotic prophylaxis using
sulfamethoxazole 200 mg plus trimethoprim 40 mg for 6 weeks.
Results: Ninety-eight and 76 patients were treated with experimental and control treatments, respec-
tively. At 12 months after treatment, 69 and 109 UTIs were detected in the experimental and control
groups, respectively. The proportion of patients free from UTIs was signiﬁcantly higher in the experi-
mental than in the control group (36.7% vs. 21.0%; p ¼ 0.03). Experimental treatment was well tolerated
and none of the patients stopped it.
Conclusion: The intravesical instillation of HA þ CS is more effective than long-term antibiotic prophy-
laxis for preventing recurrent bacterial cystitis.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Urinary tract infections (UTIs) are common in the female po-
pulation [1]. Their recurrence rate is high, reaching 35%, and it
generally occurs within 3e6 months [2,3]. Over a lifetime, aboutand Gynecology, University
ina, Italy.
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of the manuscript.
bstetrics & Gynecology. Publishedhalf of women have at least one episode of UTI requiring antibiotic
therapy [2]. Currently, as with many other common pathologies,
there is no permanent cure for UTI, which often requires a life-long
management plan with the goal of maximizing the use of medical
treatment [4,5].
UTIs are usually caused by a single pathogen, such as Escherichia
coli (80%) or Staphylococcus saprophyticus (10e15%) [1]. Less
frequently, Klebsiella pneumoniae, Enterobacter cloacae, Proteus
species or Enterococcus species can also be found [3]. Acute UTIs are
traditionally treated by intermittent or prolonged antibioticby Elsevier Taiwan LLC. All rights reserved.
Table 1
Demographic characteristics of study patients.
Experimental group Control group pa
Patients (n) 98 76 d
Age, y (mean ± SD) 36.4 ± 12.5 39.1 ± 13.1 0.168
BMI (mean ± SD) 25.6 ± 6.7 25.9 ± 5.8 0.757
BMI ¼ body mass index; SD ¼ standard deviation.
a Differences were analyzed by independent samples t test.
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results. For this reason, in recent years, the interest in ﬁnding new
therapeutic and prophylactic drugs has grown signiﬁcantly. Lite-
rature exists on estrogen cream, cranberry juice, and immunosti-
mulatory vaccines but their effects have not yet been proven [6e8].
A new proposal of treatment for UTI consists of hyaluronic acid
(HA) instillations [2]. Its use in clinical practice is based on the
pathogenic mechanism involved in the development of UTI, and of
recurrent infections [2]. In fact, it is likely that the interaction be-
tween bacteria and epithelial cells lining the bladder wall plays a
signiﬁcant role [2,9]. In particular, the glycosaminoglycan (GAG)
layer lining the transitional bladder epithelium seems to be the
most important element implicated in this process. This layer forms
a bloodeurine barrier, separating the uroepithelium fromurine and
thereby preventing the adherence of bacteria, crystals and other
toxic urinary components [5,10,11]. In contrast, a damaged GAG
layer may lead to direct exposure of the uroepithelium to injurious
urine components. This leads to an increased risk of bacterial
adherence and infection [11]. Therefore, impairment or partial
disruption of this layer has been postulated as a causative factor in
the development of interstitial cystitis and bladder carcinoma
[10,12,13].
HA is a major mucopolysaccharide component of the extracel-
lular matrix of most tissues and constitutes an important propor-
tion of bladder surface GAGs. Chondroitin sulfate (CS) is also a
proteoglycan present in the GAG layer and is an important
component for bladder mucosal integrity [14,15]. Both HA and CS
have been administered orally and/or intravesically in patients with
interstitial cystitis to restore integrity of the bladder mucosa [16].
Positive outcomes obtained in the management of interstitial
cystitis suggest that a similar therapeutic approach might be
beneﬁcial for treating recurrent UTI [2].
Based on these considerations, the present study compared
HA þ CS intravesical instillation with long-term antibiotic pro-
phylaxis in terms of efﬁcacy and tolerability in women with
recurrent UTI.
Materials and methods
The study protocol was approved by the local Institutional Re-
view Board and written informed consent was obtained from each
patient for the use of their data for research purposes.
We retrospectively selected two different cohorts of patients
treated for recurrent bacterial cystitis and who received two
different therapeutic strategies.We selected them in three different
settings in Palermo (Italy): “Villa Soﬁa-Cervello” Hospital,
“P. Giaccone”University Hospital, and “Triolo-Zancla Clinic”. Patient
selection was based on documented history of recurrent bacterial
cystitis deﬁned, according to the European Association of Urology
(EAU) criteria [17], as at least three episodes of uncomplicated
cystitis in the past year, with clinical symptoms and/or positive
culture for each episode (a positive culture being deﬁned as the
isolation of >103 colony-forming units of a uropathogen per milli-
liter of urine).
Cases (experimental group) were women who received intra-
vesical instillations of a sterile solution of high concentration of HA
(1.6% w/v e 800 mg/50 mL) and CS (2% w/v e 1 g/50 mL) in 50 mL
water with calcium chloride (iAluRil; IBSA Farmaceutici, Lodi, Italy)
from January 2011 to January 2012. The instillation was admini-
stered slowly using an 8/10 F Nelaton silicon catheter under sterile
conditions (after removal of any residual urine). Urine culture was
always performed 3 days before the instillation. If a patient
developed UTI during the treatment phase, instillations were
delayed until urine culture results were negative. After instillation,
the patients were asked to retain the instilled solution in thebladder for 2 hours and then advised to continue their normal
habits. The patients received treatment every week during the 1st
month and then once monthly for 4 months.
The control group included women who received traditional
therapy for recurrent cystitis based on long-term antibiotic pro-
phylaxis using sulfamethoxazole 200 mg plus trimethoprim 40 mg
(Bactrim; Roche, Milan, Italy) once daily for 6 weeks, during
December 2009 to December 2010.
For cases and controls, the exclusion criteria were: previous
urinary tract surgery; previous malignancy; diabetes mellitus;
radiotherapy; use of prophylactic antibiotic before, during or after
bladder instillations; use of any additional drugs and/or supple-
ments; patients with congenital and acquired urogenital abnor-
malities; and all women who used spermicides or intrauterine
devices.
In addition, we included in the ﬁnal analysis only women who
underwent an initial assessment before treatment, including fre-
quency and severity (using an analog visual scale from 0 to 10) of
past UTI, the causative pathogens, and clinical and radiological
evaluation with ultrasonography and cystoscopy; patients with
clinical charts complete for detailed information on adverse events
and appearance of any new UTI during treatment; patients who
receive complete follow-up visits as commonly performed in our
practice for recurrent cystitis (outpatient visits were performed at 1
month, 3 months, 6 months and 12 months after the end of
treatment); and patients who underwent outcome assessment
addressing UTI status (cystitis recurrence stated on clinical basis
conﬁrmed by urine analysis and positive culture).
Statistical analysis was performed with SPSS for Windows
version 17.0 (SPSS Inc., Chicago, Illinois, USA). Datawere reported as
mean and standard deviation. Differences between categorical
groups were analyzed by Fisher's exact test and between contin-
uous variables by independent samples t test. In all statistical an-
alyses, the level of signiﬁcance was set at p ¼ 0.05.Results
Ninety-eight and 76 patients were treated in the experimental
and control groups, respectively.
There was no difference between the experimental and control
groups for age and body mass index (Table 1). During the course of
HA þ CS treatment, eight episodes of UTI were detected. In these
cases, the instillations were delayed until urine culture results were
negative.
We excluded 12 patients as follows: three with previous urinary
tract surgery, ﬁve with diabetes mellitus, one who had radio-
therapy, and three with use of additional drugs and/or
supplements.
During the 12 months follow up, 69 and 109 episodes of UTI
were detected in the experimental and control groups, respectively
(Table 2). In both groups, E. coliwas the most common pathogen in
the recurrent episodes, and was identiﬁed in 69.3% of cases. The
second most common agent was Klebsiella (identiﬁed in 28.2% of
cases). All patients received suitable antibiotic treatment.
Table 2
Characteristics of UTIs in both groups after 12 months of follow up.
Group Experimental Control pa
Patients (n) 98 76 d
No. of UTIs 69 109 d
Patients with UTIs, n (%) 62 (63.3) 60 (78.9) 0.03
Patients with 1 recurrence, n (%) 57 (58.2) 24 (31.6) 0.001
Patients with 2 recurrences, n (%) 3 (3.1) 23 (30.3) < 0.0001
Patients with 3 recurrences, n (%) 2 (2.0) 13 (17.1) 0.001
UTI ¼ urinary tract infection.
a Differences were analyzed Fisher's exact test.
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higher than seven, were detected in 39.6% of cases (27/69 episodes
with positive urine cultures) and 65.2% of cases (71/109 episodes
with positive urine cultures) in the experimental and control
groups, respectively (p ¼ 0.001). The main symptoms were acute
dysuria, frequency, urgency, and pelvic pain. Data on the distribu-
tion of UTI episodes during follow up are reported in Figure 1.
At 12 months after treatment, 36 (36.7%) and 16 (21.0%) pa-
tients in the experimental and control groups, respectively, were
free from UTI (p ¼ 0.03; Table 2). All women tolerated the
HA þ CS instillations; in most cases (78%), mild or moderate pain
or burning was reported during instillation, but only in 22 cases
was anti-inﬂammatory therapy necessary to relieve the symp-
toms. None of the patients stopped HA therapy. No serious
adverse events were reported during the treatment phase in
both groups.
Discussion
This retrospective analysis demonstrated that HA þ CS intra-
vesical instillation is more effective than traditional antibiotic
prophylaxis in terms of prevention of UTI recurrence. In addition, it
is a feasible and well-accepted treatment. We observed a different
ratio of episodes of UTI in the two treatment groups after 12
months of follow up. In particular, the percentage of patients who
developed two or three episodes of UTI was mainly found in the
group treated with antibiotic therapy. However, the overall per-
centage of patients with only one episode of UTI was signiﬁcantly
higher in women who received HA þ CS intravesical instillations.
With reference to the distribution of UTI episodes during follow up,
it should be emphasized that, while in the 1st month, recurrence
was lower with antibiotic therapy, after 12 months of treatment,
the number of recurrences was signiﬁcantly lower in the popula-
tion treatedwith HAþ CS (Figure 1). Moreover, at 12months follow
up, 36.7% of patients who received instillation of HA þ CS were freeFigure 1. Distribution of urinary tract infection episodes during follow-up visits.from any UTI episodes. It could be the result of long-term repair and
consolidation of the urothelial GAG layer. This observation is in
agreement with those reported by Damiano et al [2]. Finally, we
found a signiﬁcant difference between the two treatment groups
with regard to the onset of symptoms related to the UTI.
The standard treatment for women with recurrent UTI consists
of intermittent or prolonged antibiotic therapy (with variable doses
and duration of administration), although it is a method with
obvious limitations. Persistence of infection and emergence of
resistant bacteria are themost commonproblems [3,11,18]. Changes
in the urothelial coating, mainly with a marked reduction in GAGs,
can compromise the entire functionality of the urothelium andmay
contribute to determining different clinical conditions, such as
interstitial cystitis, idiopathic detrusor overactivity, and stress uri-
nary incontinence [19]. HA prevents bacterial adherence, repairing
the GAG layer of the uroepithelium, while antibiotic therapy aims to
eradicate infection.
In 2004, Constantinides et al [11] reported the ﬁrst study on
humans regarding the efﬁcacy of GAG layer substitution for pre-
venting recurrent bacterial cystitis. A decrease in the rate of
recurrent UTI with HA treatment was shown [11].
Subsequently, Lipovac et al [14] evaluated the efﬁcacy of HA in
20 women with a history of recurrent UTIs. Nine intravesical in-
stillations were administered over 6 months. Thirteen patients
(65%) were free from recurrence until the end of the study, and
the number of infections per year per patient was signiﬁcantly
reduced from 4.99 to 0.56. The small sample size was a limitation
in that study [14]. More recently, in a prospective randomized
placebo-controlled study, Damiano et al [2] showed the efﬁcacy of
combined HA þ CS intravesical instillations in the prevention of
recurrent bacterial cystitis. The authors demonstrate that intra-
vesical HA þ CS treatment signiﬁcantly reduced the incidence of
UTI with a reduction of absolute risk of 77% of recurrent UTI at 12
months follow up, when compared with patients treated with
placebo. In 2012, De Vita and Giordano [20] compared the
HA þ CS instillation and the antibiotic prophylaxis in the pre-
vention of recurrent UTI in a randomized controlled trial. They
observed a signiﬁcant reduction of the incidence of recurrent
cystitis after 12 months of follow up in the group treated with
HA þ CS instillation. They also underline an improvement of
sexual function [20].
In our series, we also used a combined high concentration of HA
and CS to signiﬁcantly reduce the production of proinﬂammatory
cytokines and allow correct repair of the protective layer of the
urothelial coating [20]. We compared this treatment to antibiotic
therapy and we tried to prove the efﬁcacy of the product admi-
nistered only for 4 months (as it was proposed by Costantinides
et al [11]), to assess if it were feasible to obtain the same or a greater
effectiveness than standard antibiotic therapy, using the minimum
duration of instillation therapy. Moreover, we reported the data of a
large population sample.
A limitation of our study was the retrospective analysis, which
could have been a source of bias. We cannot be certain, for example,
that patients reported all infections to the clinicians. Moreover, the
follow-up period was limited to 12 months. A treatment with
intravesical instillations is, obviously, less comfortable than taking
an oral antibiotic, although in our series, none of the patients
stopped HA therapy and no serious adverse events were reported.
In contrast, it is necessary to take possible antibiotic side effects and
the impact of increased antimicrobial resistance into consideration
[2,20]. Moreover, some women would prefer not to take antimi-
crobials over an extended period of time [21].
In conclusion, our data, although preliminary, show the validity
of this new therapeutic option, which could permit us to avoid
repeated and harmful use of antibiotic therapy. Further randomized
G. Gugliotta et al. / Taiwanese Journal of Obstetrics & Gynecology 54 (2015) 537e540540trials on a larger sample population could also help to conﬁrm the
utility of this protocol.Conﬂicts of Interest
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